Moderna’s Shift to Cancer Company Lifts Stock Up 177%
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted.
But it was busy working on something else.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.nytimes.com — the content belongs to The New York Times.